Kyntra Bio (KYNB) Return on Assets (2015 - 2026)

Kyntra Bio (KYNB) posted Return on Assets of 0.02% for Q1 2026, up 2.0% sequentially from 0.02% in Q4 2025, and up 1.0% YoY from 0.02% in Q1 2025.

Kyntra Bio (KYNB) Return on Assets (2015 - 2026) Analysis & Trends

Kyntra Bio has reported Return on Assets for 12 years, with the latest figure at 0.02% in Q1 2026.

Quarterly Return on Assets rose 1.0% year-over-year to 0.02% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.02% (up 1.0% YoY) and the FY2025 annual result came in at 0.01%, up 1.0% from the prior year.
Return on Assets advanced to 0.02% in Q1 2026 per KYNB's latest filing, from 0.02% in the prior quarter.
Over five years, Return on Assets peaked at 0.02% in Q1 2026 and troughed at 0.01% in Q4 2023.
A 5-year average of 0.0% and a median of 0.0% in 2024 frame the typical range for Return on Assets.
The sharpest annual moves came in 2022 and 2025: Return on Assets changed 0 bps in 2022, then rose 2 bps in 2025.
Over 5 years, Return on Assets stood at 0.0% in 2022, then plunged by 51 bps to 0.01% in 2023, then jumped by 160 bps to 0.0% in 2024, then jumped by 327 bps to 0.02% in 2025, then grew by 2 bps to 0.02% in 2026.
According to Business Quant data, Return on Assets over the past three periods registered 0.02%, 0.02%, and 0.02% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROA (Qtr)
1	Vertex Pharmaceuticals	140.01 Bn	132.16 Bn	2.84 Bn	0.00%
2	Regeneron Pharmaceuticals	86.79 Bn	78.79 Bn	3.93 Bn	0.00%
3	Argenx Se	65.29 Bn	60.11 Bn	1.37 Bn	-
4	Moderna	60.18 Bn	55.04 Bn	52.00 Mn	0.00%
5	BeOne Medicines	42.17 Bn	37.07 Bn	1.53 Bn	0.00%
6	Alnylam Pharmaceuticals	31.55 Bn	28.24 Bn	992.69 Mn	0.00%
7	BioNTech SE	28.45 Bn	10.06 Bn	668.28 Mn	0.00%
8	Insmed	27.45 Bn	26.29 Bn	358.27 Mn	0.00%
9	Royalty Pharma	27.19 Bn	26.36 Bn	-	0.00%
10	Kyntra Bio	29.96 Mn	29.96 Mn	1.47 Mn	0.02%

Download Data